Pharmaceutical Executive, March 2016 Issue (PDF)

Pharmaceutical Executive, March 2016 Issue (PDF)

March 1, 2016

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-03-01-2016

Volume 36

Issue 3

Click the title above to open the Pharmaceutical Executive March 2016 issue in an interactive PDF format.

External Link - PharmExec_ Regular Issue _March2016.pdf

Download Issue PDF

Articles in this issue

Beyond 2020: Building Strategic Coherence in the New Health Economy

What Errors Do We Miss in Clinical Trials?

Data Disclosure: Sealing the Error Envelope

Vaccines 2016: Big Bets for Global Threats

Drug Delivery Roundtable: More than the Pill

Can FDA Control Drug Prices?

Orphans of the Storm

Country Report: The Netherlands

Pharmaceutical Executive, March 2016 Issue (PDF)

Related Content

Emerging Biopharma Launches: Strategizing in Today’s Global Market

Mike Hollan

March 13th 2025

Article

A look at the current landscape and how young companies can set the stage for product launch.

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs

February 18th 2025

Podcast

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.

Pre-Launch Prep for Emerging Biopharmas: Data First, Then the Rest

Todd Foster;Yair Markovits

March 13th 2025

Article

Making early commercial data and analytics decisions for launch cen future-proof their data management.

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs

February 10th 2025

Podcast

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.

Phase III Trial Data Show Vepdegestrant Produces Encouraging Outcomes in ER+/HER2- Advanced or Metastatic Breast Cancer

Don Tracy, Associate Editor

March 13th 2025

Article

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+/HER2- advanced or metastatic breast cancer.